The first article in our new 'Statin Series' will address the use of the therapy among patients with heart failure, the efficacy and safety assessment via three major studies- Corona, GISSI-HF and TOPCAT, and selection of the type of statin that will offer the best clinical outcome.

The usefulness and efficiency of statins are undeniable. In patients with medium, moderate, and high cardiovascular risk, they decrease mortality and cardiovascular events. Nonetheless, multiple users experience muscle complaints that add to treatment interruption. This is seen as an obstacle to preserving long-term statin adhesion. While the risk of myopathy identified in randomized clinical trials is about 1-4 per 10,000 patients over five years, the real-life occurrence of statin-associated muscle symptoms is far higher, approaching 10-20%. To alleviate statin intolerance, it is generally advised to change the statin form and dose after a brief washout time. However, a safer approach to reduce side effects and boost adherence could be to use statins carefully in different clinical scenarios.

Do statins in patients with a decreased ejection fraction reduce complicated outcomes?